BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Smolders EJ, Jansen AME, Ter Horst PGJ, Rockstroh J, Back DJ, Burger DM. Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update. Clin Pharmacokinet 2019;58:1237-63. [PMID: 31114957 DOI: 10.1007/s40262-019-00774-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Yu M, Chen P, Dai C, Hu T, Huang C, Huang Y, Hung C, Lin C, Liu C, Liu C, Peng C, Lin H, Kao J, Chuang W. 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. Journal of the Formosan Medical Association 2020;119:1135-57. [DOI: 10.1016/j.jfma.2020.04.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 12.0] [Reference Citation Analysis]
2 Stanciu C, Muzica CM, Girleanu I, Cojocariu C, Sfarti C, Singeap AM, Huiban L, Chiriac S, Cuciureanu T, Trifan A. An update on direct antiviral agents for the treatment of hepatitis C. Expert Opin Pharmacother 2021;22:1729-41. [PMID: 33896315 DOI: 10.1080/14656566.2021.1921737] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Balatow P, Sandlin A, Cory TJ. An evaluation of ledipasvir + sofosbuvir for the treatment of chronic hepatitis C infection. Expert Opin Pharmacother 2021;:1-8. [PMID: 34157923 DOI: 10.1080/14656566.2021.1943359] [Reference Citation Analysis]
4 Aboras SI, Abdine HH, Ragab MAA, Korany MA. A Review on Analytical Strategies for the Assessment of Recently Approved Direct Acting Antiviral Drugs. Crit Rev Anal Chem 2021;:1-23. [PMID: 34138669 DOI: 10.1080/10408347.2021.1923456] [Reference Citation Analysis]
5 Bohorquez H, Bugeaud E, Bzowej N, Scheuermann J, Hand J, Bruce D, Carmody I, Cohen A, Joshi S, Seal J, Sonnier D, Therapondos G, Girgrah N, Anders S, Loss GE. Liver Transplantation Using Hepatitis C Virus-Viremic Donors Into Hepatitis C Virus-Aviremic Recipients as Standard of Care. Liver Transpl. 2020;. [PMID: 33098277 DOI: 10.1002/lt.25925] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 Gupta G, Yakubu I, Zhang Y, Kimball P, Kang L, Mitchell K, Ijioma S, Carroll N, Patterson J, Shinbashi M, Kumar D, Moinuddin I, Kamal L, King A, Bhati C, Levy M, Cotterell A, Khan A, Sharma A, Sterling R. Outcomes of short-duration antiviral prophylaxis for hepatitis C positive donor kidney transplants. Am J Transplant 2021. [PMID: 34212479 DOI: 10.1111/ajt.16747] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
7 Bohorquez H, Velez JCQ, Lusco M, Scheuermann J, Cohen AJ. Hepatitis C-associated focal proliferative glomerulonephritis in an aviremic recipient of a hepatitis C-positive antibody donor liver. Am J Transplant 2021;21:2895-9. [PMID: 33721396 DOI: 10.1111/ajt.16565] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Torgersen J, Newcomb CW, Carbonari DM, Rentsch CT, Park LS, Mezochow A, Mehta RL, Buchwalder L, Tate JP, Bräu N, Bhattacharya D, Lim JK, Taddei TH, Justice AC, Lo Re V 3rd. Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. J Hepatol 2021:S0168-8278(21)01950-4. [PMID: 34333102 DOI: 10.1016/j.jhep.2021.07.021] [Reference Citation Analysis]
9 Akl EM, Salah AA. Effect of new oral direct acting antiviral therapy on sexual function in male patients with hepatitis C virus. Andrologia 2020;52:e13835. [PMID: 33070383 DOI: 10.1111/and.13835] [Reference Citation Analysis]
10 Elmowafy AY, Abbas MH, Denewar AA, Mashaly ME, Shiha G, El Wasif SM, Rostaing L, Bakr MA. The effect of anemia on the efficacy and safety of treating chronic hepatitis C infection with direct-acting antivirals in patients with chronic kidney disease. Int Urol Nephrol 2021;53:749-61. [PMID: 33111161 DOI: 10.1007/s11255-020-02656-y] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Ing Lorenzini K, Girardin F. Direct‐acting antiviral interactions with opioids, alcohol or illicit drugs of abuse in HCV‐infected patients. Liver Int 2019;40:32-44. [DOI: 10.1111/liv.14283] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
12 Wang SJ, Huang CF, Yu ML. Elbasvir and grazoprevir for the treatment of hepatitis C. Expert Rev Anti Infect Ther 2021;19:1071-81. [PMID: 33428488 DOI: 10.1080/14787210.2021.1874351] [Reference Citation Analysis]
13 Kuo MH, Tseng CW, Lee CH, Tseng KC. Drug-drug interactions between direct-acting antivirals and statins in the treatment of chronic hepatitis C. Tzu Chi Med J 2020;32:331-8. [PMID: 33163377 DOI: 10.4103/tcmj.tcmj_247_19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Pietrosi G, Russelli G, Barbera F, Curcio G, Tuzzolino F, Gallo A, Volpes R, Vizzini G, Conaldi PG. Direct-acting antivirals ability to clear intestinal HCV-RNA in liver transplant patients. Transpl Infect Dis 2020;22:e13345. [PMID: 32495971 DOI: 10.1111/tid.13345] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Jiang X, Tan J, Wang Y, Chen J, Li J, Jiang Z, Quan Y, Jin J, Li Y, Cen S, Li Y, Peng Z, Li Z. 2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action. J Med Chem 2020;63:5972-89. [PMID: 32378892 DOI: 10.1021/acs.jmedchem.0c00232] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Cheng TS, Liang PC, Huang CF, Yeh ML, Huang CI, Lin ZY, Chen SC, Huang JF, Dai CY, Hsieh PH, Chuang WL, Yu ML. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment. Kaohsiung J Med Sci. 2021;37:334-345. [PMID: 33151016 DOI: 10.1002/kjm2.12315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Schwerk J, Negash A, Savan R, Gale M Jr. Innate Immunity in Hepatitis C Virus Infection. Cold Spring Harb Perspect Med 2021;11:a036988. [PMID: 32341066 DOI: 10.1101/cshperspect.a036988] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
18 Zappulo E, Scotto R, Buonomo AR, Maraolo AE, Pinchera B, Gentile I. Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C. Expert Opin Pharmacother 2020;21:261-73. [PMID: 31914336 DOI: 10.1080/14656566.2019.1697674] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Sise ME, McQuaid T, Martin P. Sofosbuvir-based hepatitis C therapies in patients with chronic and end-stage kidney disease. Nephrol Dial Transplant 2021:gfab072. [PMID: 33848334 DOI: 10.1093/ndt/gfab072] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
20 Practice Committee of the American Society for Reproductive Medicine. Electronic address: asrm@asrm.org., Practice Committee of the American Society for Reproductive Medicine. Recommendations for reducing the risk of viral transmission during fertility treatment with the use of autologous gametes: a committee opinion. Fertil Steril 2020;114:1158-64. [PMID: 33280723 DOI: 10.1016/j.fertnstert.2020.09.133] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
21 Feng Z, Zhang J, Tan W, Wang C, Chen Q, Shen C, Fan H, Zhang Y, Huang P, Yue M. Efficacy and Safety of Direct-Acting Antivirals in Kidney Transplantation From HCV-Viremic Donors to Negative Recipients: A Meta-Analysis. Front Med (Lausanne) 2022;9:802686. [PMID: 35665327 DOI: 10.3389/fmed.2022.802686] [Reference Citation Analysis]
22 Lalanne S, Jézéquel C, Tron C, Verdier MC, Mercerolle M, Pronier C, Guyader D, Lemaitre F. Therapeutic Drug Monitoring-Guided Crushed Sofosbuvir-Velpatasvir Treatment: A Case Study. Ther Drug Monit 2020;42:163-4. [PMID: 32195986 DOI: 10.1097/FTD.0000000000000718] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Spera AM. Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review. World J Hepatol 2022; 14(3): 525-534 [DOI: 10.4254/wjh.v14.i3.525] [Reference Citation Analysis]
24 Gupta G, Yakubu I, Bhati CS, Zhang Y, Kang L, Patterson JA, Andrews-Joseph A, Alam A, Ferreira-Gonzalez A, Kumar D, Moinuddin IK, Kamal L, King AL, Levy M, Sharma A, Cotterell A, Reichman TW, Khan A, Kimball P, Stiltner R, Baldecchi M, Brigle N, Gehr T, Sterling RK. Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients. Am J Transplant 2020;20:739-51. [PMID: 31652392 DOI: 10.1111/ajt.15664] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 16.7] [Reference Citation Analysis]
25 El-Baraky IA, Abbassi MM, Ebied FS, Hassany M, Sabry NA, El-Sayed MH. Beta-thalassemia major alters sofosbuvir/ledipasvir exposure in Hepatitis C virus infected adolescent patients. Clin Res Hepatol Gastroenterol 2021;45:101747. [PMID: 34186262 DOI: 10.1016/j.clinre.2021.101747] [Reference Citation Analysis]
26 Kempker RR, Alghamdi WA, Al-Shaer MH, Burch G, Peloquin CA. A Pharmacology Perspective of Simultaneous Tuberculosis and Hepatitis C Treatment. Antimicrob Agents Chemother 2019:AAC. [PMID: 31591118 DOI: 10.1128/AAC.01215-19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
27 Ramirez S, Fernandez-Antunez C, Mikkelsen LS, Pedersen J, Li YP, Bukh J. Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c. Antimicrob Agents Chemother 2020;64:e01888-19. [PMID: 31818814 DOI: 10.1128/AAC.01888-19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
28 Marzolini C, Kuritzkes DR, Marra F, Boyle A, Gibbons S, Flexner C, Pozniak A, Boffito M, Waters L, Burger D, Back DJ, Khoo S. Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications. Clin Pharmacol Ther 2022. [PMID: 35567754 DOI: 10.1002/cpt.2646] [Reference Citation Analysis]
29 Groaz E, De Clercq E, Herdewijn P. Anno 2021: Which antivirals for the coming decade? Annu Rep Med Chem 2021;57:49-107. [PMID: 34744210 DOI: 10.1016/bs.armc.2021.09.004] [Reference Citation Analysis]
30 Trilianos P, Tsangaris A, Tawadros A, Deshpande V, Pyrsopoulos N. The Reliability of Fibro-test in Staging Orthotopic Liver Transplant Recipients with Recurrent Hepatitis C. J Clin Transl Hepatol 2020;8:9-12. [PMID: 32274340 DOI: 10.14218/JCTH.2019.00038] [Reference Citation Analysis]
31 Kuntzen C, Bagha Z. The Use of Hepatitis C Virus–Positive Organs in Hepatitis C Virus–Negative Recipients. Clinics in Liver Disease 2022. [DOI: 10.1016/j.cld.2022.01.012] [Reference Citation Analysis]
32 Chen WM, Wei KL, Tung SY, Shen CH, Chang TS, Yen CW, Hsieh YY, Chiu WN, Hu JH, Lu SN, Hung CH. High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy. J Formos Med Assoc 2020;119:1593-600. [PMID: 32839045 DOI: 10.1016/j.jfma.2020.08.010] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Zhuang L, Li J, Zhang Y, Ji S, Li Y, Zhao Y, Li B, Li W, Quan M, Duan Y, Zhao H, Cheng D, Wang X, Ou W, Xing H. Real-World Effectiveness of Direct-Acting Antiviral Regimens against Hepatitis C Virus (HCV) Genotype 3 Infection: A Systematic Review and Meta-Analysis. Ann Hepatol 2021;23:100268. [PMID: 33059055 DOI: 10.1016/j.aohep.2020.09.012] [Reference Citation Analysis]